Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
- Phase III study shows close to?9/10 patients who received Cosentyx? 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early as week 3[1]
- Results strengthen unique position of Cosentyx as a rapid and long-lasting complete treatment of psoriatic disease, with over 200,000 patients treated worldwide[2]
- Data is being presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.